Industries > Pharma > Global Biosimilars and Follow-On Biologics Market 2017-2027

Global Biosimilars and Follow-On Biologics Market 2017-2027

Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones

PUBLISHED: 02 May 2017
PAGES: 318
PRODUCT CODE: PHA0188

Clear
WOOCS 2.2.1

The global biosimilars and follow-on biologics market is expected to grow at a CAGR of 38.8% in the first half of the forecast period and CAGR of 11.3% in the second half of the forecast period. The market is estimated at $5.31bn in 2016 and $41.07bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 318-page report you will receive 128 tables and 68 figures – all unavailable elsewhere.

The 318-page report provides clear detailed insight into the global biosimilars and follow-on biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Global Biosimilars and Follow-On Biologics Market 2017-2027

Report Scope

Global Biosimilars and Follow-on Biologics Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2027 for 8 individual therapeutic submarkets:
– Monoclonal antibodies (mAbs)
– Fusion proteins
– Insulin
– Erythropoietin (EPO)
– Granulocyte colony-stimulating factor (G-CSF)
– Interferons
– Growth hormones
– Fertility hormones

• This report also shows revenue to 2027 for 12 individual submarkets within the above segments:
– Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab
– Human insulin, insulin analogues, insulin glargine and insulin lispro
– Interferon alfa and interferon beta
– Etanercept

• Our analyses show individual revenue forecasts to 2027 for 12 national markets:
– US
– Japan
– Germany, France, UK, Italy and Spain
– China, India, South Korea, Russia and Brazil

• Our study discusses pressures, opportunities and other events affecting the biosimilars industry and market from 2016, including these influences:
Strategies for developing biosimilars – needs, demand, challenges and opportunities
Guidelines from regulators (FDA, EMA and others)
Patent challenges and data exclusivity for biopharmaceuticals
– Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers and increasing demand for lower-cost biologicals
– Developments in technology and operations for biosimilar drug production.

Visiongain’s study is intended for anyone requiring commercial analyses for the biosimilars and follow-on biologics market. You find data, trends and predictions.

Buy our report today Global Biosimilars and Follow-On Biologics Market 2017-2027: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Biosimilars and Follow-On Biologics Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Biosimilars and Follow-On Biologics Market 2017-2027


Latest Pharma news

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

READ

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Categories